Skip to content

The implanted spinal cord stimulator system is used to treat orthostatic hypotension in patients with multiple system atrophy

The implanted spinal cord stimulator system is used to treat orthostatic hypotension in patients with multiple system atrophy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109336
Enrollment
Unknown
Registered
2025-09-17
Start date
2025-09-22
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MSA,Multiple system atrophy

Interventions

Intervention group:(1) Patients should receive comprehensive health education before surgery.(2) The implantation of plate electrodes under general anesthesia requires a surgical incision method, invo

Sponsors

Department of Neurology, Xuanwu Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meets the diagnostic criteria for possible or probable multiple system atrophy (MSA) according to Gilman's criteria; 2.Age >50 years; 3.Presence of orthostatic dizziness and orthostatic hypotension (defined as a drop in systolic blood pressure >=30 mmHg upon standing); 4.History of recurrent syncope; 5.Failure or intolerance to pharmacological treatment; 6.Patient and family members demonstrate adequate comprehension and communication abilities, voluntarily participate, and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1.Cognitive dysfunction; 2.Supine hypertension (defined as supine blood pressure >160/90 mmHg after antihypertensive medication); 3.Secondary autonomic dysfunction caused by diabetes mellitus, spinal cord injury, amyloidosis, uremia, or other conditions; 4.Structural heart disease, including severe arrhythmia, valvular heart disease, myocardial infarction, or cardiac insufficiency; 5.Implanted cardiac devices; 6.Severe anxiety or depression; 7.Significant visual impairment; 8.Poor compliance or other conditions deemed unsuitable for trial participation by investigators.

Design outcomes

Primary

MeasureTime frame
Orthostatic blood pressure and heart rate;

Secondary

MeasureTime frame
Walking Distance;Weekly Frequency of Syncope;Weekly Frequency of Presyncope;Variability of blood pressure;Heart Rate;Activities of Daily Living (ADL) Scale;

Countries

China

Contacts

Public ContactLin Hua

Department of Neurology, Xuanwu Hospital, Capital Medical University

linhuadoctor@163.com+86 135 2016 3017

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026